Exhale-Dx
Pre-clinical- Indications
- Asthma, COPD
Company intelligence / Profile preview
Applied Nanodetectors has developed the Exhale-Dx™ point-of-care breath diagnostic platform for asthma self-management. Early results show high accuracy in identifying patients with asthma and predicting attacks up to three days in advance using AI-driven analysis of exhaled biomarkers. The company aims to extend this predictive window further. The solution includes a device, software for disease management, cloud connectivity for healthcare professionals, and personalized action plans. No traditional clinical trial data as would be seen with therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Applied Nanodetectors.